Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months.
暂无分享,去创建一个
C. McDougle | D. Posey | F. Volkmar | J. McGough | L. Ritz | J. McCracken | Andrés Martin | M. Davies | M. Grados | L. Scahill | D. McMahon | L. E. Arnold | B. Vitiello | E. Tierney | K. Koenig | M. Aman | Jill Hollway | N. Kline | James Robinson | J. Ghuman | N. Swiezy | Patricia L. Nash | R. Lindsay | N. Gonzalez | A. Kohn | P. Cronin | B. Shah | Allison Lancor | Deirdre H. Carroll | K. Krieger | L. Lee | Bhavik Shah | Arlene E. Kohn | L. Arnold | Jill A. Hollway | Kennedy Krieger | Louise Ritz | Kathleen Koenig
[1] M. Crismon,et al. Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II. , 2004, Journal of the American Academy of Child and Adolescent Psychiatry.
[2] C. McDougle,et al. Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. , 2004, The American journal of psychiatry.
[3] C. McDougle,et al. Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. , 2003, Journal of the American Academy of Child and Adolescent Psychiatry.
[4] G. Maislin,et al. Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. , 2002, Journal of the American Academy of Child and Adolescent Psychiatry.
[5] C. McDougle,et al. Methodological issues in designing a multisite trial of risperidone in children and adolescents with autism. , 2001, Journal of child and adolescent psychopharmacology.
[6] P. Brovedani,et al. Open trial of risperidone in 24 young children with pervasive developmental disorders. , 2001, Journal of the American Academy of Child and Adolescent Psychiatry.
[7] E. Fombonne,et al. Pervasive developmental disorders in preschool children. , 2001, JAMA.
[8] J. Buitelaar,et al. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. , 2001, The Journal of clinical psychiatry.
[9] C. McDougle,et al. Assessment in Multisite Randomized Clinical Trials of Patients with Autistic Disorder: The Autism RUPP Network , 2000, Journal of autism and developmental disorders.
[10] C. McDougle,et al. Brief Report: Two-Year Control of Behavioral Symptoms with Risperidone in Two Profoundly Retarded Adults with Autism , 1999, Journal of autism and developmental disorders.
[11] C. McDougle,et al. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. , 1998, Archives of general psychiatry.
[12] G. Dawson,et al. The Vineland Adaptive Behavior Scales: Supplementary Norms for Individuals with Autism , 1998, Journal of autism and developmental disorders.
[13] J. Overall,et al. Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.
[14] A. Couteur,et al. Autism Diagnostic Interview-Revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders , 1994, Journal of autism and developmental disorders.
[15] S D Imber,et al. Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collaborative Research Program dataset. , 1993, Archives of general psychiatry.
[16] R. Perry,et al. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children , 1989, Journal of autism and developmental disorders.
[17] G. Simpson,et al. A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS , 1970, Acta psychiatrica Scandinavica. Supplementum.
[18] S. Havercamp,et al. Factor analysis and norms for parent ratings on the Aberrant Behavior Checklist-Community for young people in special education. , 2002, Research in developmental disabilities.
[19] P. Muglia,et al. Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. , 2000, Journal of child and adolescent psychopharmacology.
[20] C. McDougle,et al. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Background and rationale for an initial controlled study of risperidone. , 2000, Child and adolescent psychiatric clinics of North America.
[21] M. Rutter,et al. Genetics and child psychiatry: II Empirical research findings. , 1999, Journal of child psychology and psychiatry, and allied disciplines.
[22] J. Bregman,et al. Diagnosing Autism: Analyses of Data from the Autism Diagnostic Interview , 1997, Journal of Autism and Developmental Disorders.
[23] M. Wiznitzer,et al. An open clinical trial of risperidone monotherapy in young children with autistic disorder. , 1997, Psychopharmacology bulletin.
[24] S. Fisman,et al. Use of risperidone in pervasive developmental disorders: a case series. , 1996, Journal of child and adolescent psychopharmacology.
[25] J. Overall,et al. Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration. , 1989, Journal of the American Academy of Child and Adolescent Psychiatry.